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Abstract Insulin resistance might be associated with an
impaired ability of insulin to stimulate glucose oxidation
and inhibit lipid oxidation. Insulin action is also inversely
associated with TNF-a system and positively related to
adiponectin. The aim of the present study was to analyze
the associations between serum adiponectin, soluble TNF-a
receptors concentrations and the whole-body insulin sen-
sitivity, lipid and glucose oxidation, non-oxidative glucose
metabolism (NOGM) and metabolic ﬂexibility in lean and
obese subjects. We examined 53 subjects: 25 lean (BMI\
25 kg 9 m
-2) and 28 with overweight or obesity (BMI[
25 kg 9 m
-2) with normal glucose tolerance. Hyperinsu-
linemic euglycemic clamp and indirect calorimetry were
performed. An increase in respiratory exchange ratio in
response to insulin was used as a measure of metabolic
ﬂexibility. Obese subjects had lower insulin sensitivity,
adiponectin and higher sTNFR1 (all P\0.001) and
sTNFR2 (P = 0.001). Insulin sensitivity was positively
related to adiponectin (r = 0.49, P\0.001) and nega-
tively related to sTNFR1 (r =- 0.40, P = 0.004) and
sTNFR2 (r =- 0.52, P\0.001). Adiponectin was related
to the rate of glucose (r = 0.47, P\0.001) and lipid
(r =- 0.40, P = 0.003) oxidation during the clamp,
NOGM (r = 0.41, P = 0.002) and metabolic ﬂexibility
(r = 0.36, P = 0.007). Serum sTNFR1 and sTNFR2 were
associated with the rate of glucose (r =- 0.45, P = 0.001;
r =- 0.51, P\0.001, respectively) and lipid (r = 0.52,
P\0.001; r = 0.46, P = 0.001, respectively) oxidation
during hyperinsulinemia, NOGM (r =- 0.31, P = 0.02;
r =- 0.43, P = 0.002, respectively) and metabolic ﬂexi-
bility (r =- 0.47 and r =- 0.51, respectively, both
P\0.001) in an opposite manner than adiponectin. Our
data suggest that soluble TNF-a receptors and adiponectin
have multiple effects on glucose and lipid metabolism in
obesity.
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Introduction
It is generally agreed that decreased insulin sensitivity is an
important component in the pathogenesis of obesity, type 2
diabetes, hyperuricemia, cardiovascular disease, hyperten-
sion and polycystic ovary syndrome [1, 2]. Insulin resis-
tance might be associated with an impaired ability of
insulin to stimulate glucose oxidation and inhibit lipid
oxidation [3–5]. It might also be related to an impaired
insulin-stimulated non-oxidative glucose metabolism
(NOGM), which reﬂects the rate of glycogen synthesis,
mainly in the skeletal muscle [6–8]. The balance between
various cytokines plays an important role in modeling
insulin action, which is inversely associated with circulat-
ing pro-inﬂammatory cytokines like TNF-a [9–14] and
positively related to anti-inﬂammatory adipocytokines like
adiponectin [15–19]. Adiponectin has protective effects
against cardiovascular disease (CVD) [20]. Sheng-Chiang
Su et al. recently showed that adiponectin was signiﬁcantly
correlated with HOMA-IR and BMI might be the major
determinant of plasma adiponectin and pro-inﬂammatory
cytokines in young diabetes mellitus patients [20].
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substrates’ metabolism. There is evidence that adiponectin
has insulin-sensitizing properties [16, 18, 21] and could be
involved in glucose and lipid metabolism [5, 8, 22, 23]. It is
less clear whether adiponectin is associated more with
oxidative glucose or lipid metabolism during hyperinsuli-
nemia [5, 22, 24, 25] or NOGM [8, 21, 22, 24, 26]. In
experimental studies, recombinant adiponectin improved
insulin sensitivity, mainly by increasing fatty acid oxida-
tion [23]. Yin et al. showed that adiponectin can suppress
lipid accumulation by promoting fatty acid oxidation dur-
ing C2C12 myogenesis, rather than fatty acid hydrolysis
and synthesis [27]. Decreased adiponectin level is associ-
ated with decreased insulin-stimulated glucose uptake and
oxidation [28].
Serum levels of soluble TNF-a receptors (sTNFR1 and
sTNFR2) are supposed to reﬂect local tissue action of this
cytokine [10, 29]. There are conﬂicting data regarding the
role of TNF-a in the control of substrate utilization. TNF-
a-stimulated lipolysis was accompanied by decrease in fatty
acid oxidation in 3T3-L1 adipocytes [30]. Pellieux et al.
showed that angiotensin II decreased fatty acid oxidation
pathwayinadultratcardiomyocytesbygenerationofTNF-a
[31]. On the other hand, new data showed that TNFRs play a
physiological role to limit body weight and adiposity by
modestly increasing metabolic rate and fatty acid oxidation,
and they alter adipose tissue macrophages status [32].
Plomgaard et al. demonstrate that 4-h rhTNF-a infusion
increases whole-body lipolysis, without enhancing skeletal
muscle fat metabolism and without affecting basal glucose
turnover [33]. However, data in a human cardiac cell model
demonstrated that TNF-a reduces the expression of PGC-1a
(peroxisome proliferator–activated receptor coactivator 1 a)
which resulted in an increase in glucose oxidation rate [34].
Precise measurement of insulin sensitivity is an impor-
tant issue, and different methods are proposed [36]. There
are also simple indices of insulin action, for instance IGFBs
(insulin-like growth factor–binding proteins) [37]. How-
ever, euglycemic hyperinsulinemic clamp remains the
‘‘gold standard’’ in assessing insulin sensitivity in vivo.
The aim of the present study was to analyze the asso-
ciations between serum adiponectin, sTNFR1 and sTNFR2
concentrations and the whole-body insulin sensitivity, lipid
and glucose oxidation and NOGM by applying the eugly-
cemic clamp technique and indirect calorimetry in lean and
obese subjects.
Methods and procedures
We examined 53 subjects: 25 lean (BMI\25 kg 9 m
-2)
and 12 subjects with overweight (25 kg 9 m
-2[BMI\
30 kg 9 m
-2) (3 men and 9 women) and 16 subjects with
obesity (BMI[30 kg 9 m
-2) (3 men and 13 women). We
actively recruited the subjects to participate in the study.
Obese subjects were partly recruited from the Outpatient
Clinic of the Department of Endocrinology, Diabetology
and Internal Medicine, Medical University of Bialystok.
Additionally, overweight/obese and control subjects were
recruited from the medical staff and students. All partici-
pants had no morbid obesity, cardiovascular disease,
hypertension, infections and any other serious medical
problems and were not taking anti-inﬂammatory drugs
(within previous 3 months) or any drugs known to affect
glucose and lipid metabolism. Before entering the study,
physical examination was performed. All subjects under-
went an oral glucose tolerance test (OGTT) and had normal
glucose tolerance according to WHO criteria. All subjects
gave written informed consent before entering the study.
The study protocol was approved by the Ethics Committee
of Medical University of Bialystok, Poland.
Anthropometric measurements
BMI was calculated as body weight in kilograms divided
by height in meters squared (kg/m
2). The waist circum-
ference was measured at the smallest circumference
between the rib cage and the iliac crest, with the subject in
the standing position. Percent of body fat was estimated by
bioelectric impedance analysis using the Tanita TBF-511
Body Fat Analyzer (Tanita Corp., Tokyo, Japan).
Insulin sensitivity
Insulin sensitivity was evaluated by the euglycemic hype-
rinsulinemicclamptechniqueasdescribedbyDeFronzoetal.
[35]. Insulin (Actrapid HM, Novo Nordisk, Copenhagen,
Denmark) was given as a primed continuous intravenous
infusion for 2 h at 40 mU 9 m
-2 9 min
-1, resulting in
constant hyperinsulinemia of approximately 75 mU/l. Arte-
rialized blood glucose was obtained every 5 min, and 20%
dextrose (1.11 mol/l) infusion was adjusted to maintain
plasmaglucoselevelsat5.0 mmol/l.Theglucoseinfusionrate
approachedstablevaluesduringﬁnal40 minofthestudy,and
the rate of whole-body glucose uptake (M value) was calcu-
lated as the mean glucose infusion rate from 80 to 120 min,
corrected for glucose space and normalized per kilogram of
fat-free mass (Mffm).
Lipid and glucose oxidation
Whole-body lipid and glucose oxidation rates were mea-
sured by indirect calorimetry using the ventilated hood
technique (Oxycon Pro, Viasys Healthcare GmbH—Erich
Jaeger, Hochberg, Germany) in order to calculate lipid and
glucose oxidation from respiratory gas exchange (oxygen
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123consumption and carbon dioxide production). The device
was calibrated before each test using reference gases.
Measurements were taken while the subjects were lying in
a supine position at baseline (in the fasting state) and
during the last 30 min of the clamp study. Each study was
performed in the thermoneutral environment, after relaxing
for 15 min. NOGM was calculated by subtracting the
glucose oxidation rate during hyperinsulinemia from
whole-body glucose disposal rate. An increase in respira-
tory exchange ratio (detla RER) in response to insulin was
used as a measure metabolic ﬂexibility.
Biochemical analyses
Fasting blood samples were taken from the antecubital vein
before the beginning of the clamp for the determination of
serum lipids, sTNFR1, sTNFR2 and adiponectin concen-
trations. Samples were frozen at -70C until analyses.
Plasma glucose was measured immediately by the enzy-
matic method using glucose analyzer (YSI 2300 STAT
PLUS). Serum insulin was measured with the Medgenix
EASIA test (BioSource Europe, Nivelles, Belgium). The
minimum detectable concentration was 1.05 pg/l, and the
intra-assay and inter-assay coefﬁcients of variation (CVs)
were below 5.5 and 10%, respectively. In that method,
human and animal proinsulins present no cross-reaction.
Serum total and HDL cholesterol and triglycerides (TG)
were assessed by the enzymatic methods using commercial
kits produced by ANALCO-GBG, Poland. Concentration
of LDL cholesterol (LDL-CH) was calculated from
Friedewald’s formula: LDL-CH = total cholesterol - TG/
5 - HDL cholesterol (mg/dl).
Serum sTNFR1 and sTNFR2 were determined with the
EASIA kits (BioSource Europe). The minimum detectable
concentration was 0.05 ng/ml for sTNFR1 and 0.1 ng/ml
for sTNFR2. The intra-assay and inter-assay CVs for both
receptors were below 6.5 and 9%, respectively. sTNFR1
EASIA does not cross-react with sTNFR2. Serum adipo-
nectin was measured with the RIA Kit (Linco Research,
Inc. St. Charles, Missouri, USA) with the detection limit of
1 ng/ml and with intra-assay and inter-assay CVs below
6.3 and 9.5%, respectively.
Statistical analysis
The statistics were performed with the STATISTICA 8.0
program (StatSoft, Krakow, Poland). The variables that did
not have normal distribution were log-transformed prior to
analyses (TG, insulin). The differences between the groups
were evaluated with one-way ANOVA and with post hoc
Tukey’s honestly signiﬁcant difference test for unequal
sample sizes. When overweight and obese subjects were
pooled together, the differences between the groups were
evaluated with an unpaired Student’s t test. The relation-
ships between variables were estimated with the simple and
multiple regression analysis. The level of signiﬁcance was
accepted at P value less than 0.05.
We calculated the sample size on the basis of our pre-
vious data on insulin sensitivity (but without indirect cal-
orimetry), serum adiponectin, sTNFR1 and sTNFR2,
obtained on the population of about 300 subjects, with
similar characteristics to the study group included in the
present paper. The results of all these parameters were very
similar in these groups. On that basis, the minimal sample
size in each group to detect signiﬁcant differences at
a\0.05 and 1 - b[0.80 was n = 22 for insulin sensi-
tivity; n = 20 for serum adiponectin; n = 16 for sTNFR1;
and n = 21 for sTNFR2.
Results
The clinical characteristics of the studied groups are
shown in Table 1. Obese subjects had lower insulin sen-
sitivity and serum adiponectin concentration (P = 0.003
and P = 0.007, respectively) versus lean subject. Serum
levels of sTNFR1 and sTNFR2 were higher in the obese
group (P\0.001 and P = 0.008, respectively) versus lean
group (Table 1).
Fasting rates of lipid and glucose oxidation did not differ
between studied groups. Obese subject had higher rate of
lipid oxidation during the clamp (P = 0.003) and lower
NOGM and metabolic ﬂexibility (both P = 0.01) versus
lean group (Table 2).
Additionally, because there were no differences between
overweight and obese subjects in insulin sensitivity, serum
adiponectin, sTNFR1 and sTNFR2, we calculated data for
overweight and obese subjects pooled together. The results
of the research showed that obese/overweight subjects had
lower insulin sensitivity and serum adiponectin concen-
tration (both P\0.001). Serum levels of sTNFR1 and
sTNFR2 were higher in these group (P\0.001 and
P = 0.001, respectively).
Fasting rates of lipid and glucose oxidation also did not
differ between lean and obese/overweight groups. Obese/
overweight group had higher rate of lipid oxidation during
the clamp (P = 0.0005) and lower rate of glucose oxida-
tion during hyperinsulinemia (P = 0.01), lower NOGM
and metabolic ﬂexibility (P = 0.004 and P = 0.003,
respectively).
Insulin sensitivity was positively related to serum
adiponectin concentration (r = 0.49, P\0.001) and neg-
atively related to sTNFR1 and sTNFR2 (r =- 0.40, P =
0.004, r =- 0.52, P\0.001, respectively). Adiponectin
was related to the rate of glucose (r = 0.47, P\0.001)
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123and lipid (r =- 0.40, P = 0.003) oxidation during the
clamp (Fig. 1a, b). We also found positive correlation
between adiponectin and RER during the clamp (r = 0.43,
P = 0.001) and with NOGM (r = 0.41, P = 0.002) and
metabolic ﬂexibility (r = 0.36, P = 0.007). Serum
sTNFR1 concentration was associated with the rate of
glucose (r =- 0.45, P = 0.001) (Fig. 1c) and
lipid (r = 0.52, P\0.001) (Fig. 1d) oxidation during
hyperinsulinemia and also with NOGM (r =- 0.31,
P = 0.02) and metabolic ﬂexibility (r =- 0.47, P\
0.001). Similarly, serum sTNFR2 correlated with the rate
of glucose (r =- 0.51, P\0.001) and lipid (r = 0.46,
Table 1 Clinical and biochemical characteristics of the studied groups
Lean subjects (n = 25) Overweight subjects (n = 12) Obese subjects (n = 16) P
Age (year) 25.1 ± 5.3 25 ± 5.3 28.3 ± 7.9 0.23
M/F 6/19 3/9 3/13
BMI (kg/m
2) 21.64 ± 2.03 27.11 ± 1.77 33.89 ± 2.96 \0.0001
Waist girth (cm) 74.2 ± 6.1 85.3 ± 5.9*,*** 104.1 ± 6.9** \0.0001
Body fat (%) 23.2 ± 6.6 30.4 ± 7.5*** 42.9 ± 10.7** \0.0001
Total cholesterol (mg/dl) 172.7 ± 31.2 176.2 ± 39.2 176.9 ± 40.2 0.92
Serum TG (mg/dl) 71.3 ± 32.8 85.0 ± 32.3 179.0 ± 226.2** 0.03
HDL cholesterol (mg/dl) 60.3 ± 10.5 56.1 ± 6.2 54.4 ± 9.4 0.13
LDL cholesterol (mg/dl) 98.1 ± 31.3 98.5 ± 34.1 88.0 ± 23.8 0.58
Fasting glucose (mg/dl) 80.4 ± 7.4 84.3 ± 6.8 83.4 ± 9.6 0.29
Postload glucose (mg/dl) 75.3 ± 15.8 87.8 ± 16.1 96.2 ± 21.8** 0.002
Fasting insulin (lIU/ml) 11.9 ± 5.2 12.4 ± 4.1*** 22.3 ± 13.4** 0.001
Postload insulin (lIU/ml) 30.9 ± 19.0 47.7 ± 36.3 95.4 ± 78.2** \0.0001
M (mg 9 kgffm
-1 9 min
-1) 11.16 ± 3.07 9.01 ± 2.61 7.21 ± 3.95** 0.001
Serum adiponectin (lg/ml) 16.2 ± 4.7 12.1 ± 5.4 11.2 ± 3.2** 0.001
Serum sTNFR1 (ng/ml) 1.78 ± 0.29 2.02 ± 0.29 2.27 ± 0.35** \0.0001
Serum sTNFR2 (ng/ml) 3.80 ± 0.88 4.46 ± 0.89 4.86 ± 0.91** 0.002
Data are presented as mean ± SD
M/F Male/female, BMI Body mass index, OGTT Oral glucose tolerance test, M Whole-body glucose uptake normalized per kg of fat-free mass,
sTNFR1 Soluble TNFa receptor 1, sTNFR2 Soluble TNFa receptor 2
* P\0.05 in overweight versus lean subjects
** P\0.05 in obese versus lean subjects
*** P\0.05 in overweight versus obese subjects
Table 2 Respiratory exchange ratio, nutrient oxidation rate, NOGM and metabolic ﬂexibility before and during clamp in lean and obese subjects
Lean subjects (n = 25) Overweight subjects (n = 12) Obese subjects (n = 16) P
RER-basal 0.80 ± 004 0.80 ± 0.04 0.82 ± 0.06 0.63
RER-clamp 0.86 ± 0.04 0.82 ± 0.05 0.81 ± 0.04* 0.01
COx-basal (mg 9 kgffm
-1 9 min
-1) 1.35 ± 0.77 1.32 ± 0.68 1.81 ± 1.18 0.21
LOx-basal (mg 9 kgffm
-1 9 min
-1) 1.03 ± 0.35 1.12 ± 0.32 1.19 ± 0.60 0.47
COx-clamp (mg 9 kgffm
-1 9 min
-1) 2.32 ± 0.86 1.76 ± 0.82 1.66 ± 0.85 0.03
LOx-clamp (mg 9 kgffm
-1 9 min
-1) 0.69 ± 0.36 0.99 ± 0.38 1.18 ± 0.45* 0.001
NOGM (mg 9 kgffm
-1 9 min
-1) 8.84 ± 3.0 7.25 ± 2.35 5.55 ± 3.75* 0.007
Delta RER 0.05 ± 0.05 0.02 ± 0.05 -0.004 ± 0.05* 0.006
Data are presented as mean ± SD
RER1 Respiratory exchange ratio before clamp, RER2 Respiratory exchange ratio during clamp, REE1 Resting energy expenditure before clamp,
REE2 Resting energy expenditure during clamp, COx-basal Rate of glucose oxidation in the basal state, LOx-basal Rate of lipid oxidation in the
basal state, COx-clamp Rate of glucose oxidation during hyperinsulinemia, LOx-clamp Rate of lipid oxidation during hyperinsulinemia, NOGM
Non-oxidative glucose metabolism, delta RER Change in respiratory exchange ratio in response to hyperinsulinemia
* P\0.05 in obese versus lean subjects
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123P = 0.001) oxidation and with NOGM (r =- 0.43, P =
0.002) and metabolic ﬂexibility (r =- 0.51, P\0.001).
We observed negative correlation between waist cir-
cumference and adiponectin (r =- 0.39, P = 0.003) and
positive correlation between waist circumference and
sTNFR1 and sTNFR2 (r = 0.58, P\0.0001; r = 0.50,
P\0.0001, respectively).
In multiple regression analysis, we observed that the
relationship between M and adiponectin (b = 0.31;
P = 0.02) was independent of age, gender and waist cir-
cumference (Table 3). We observed also that the relation-
ships between glucose oxidation during the clamp and
sTNFR1 (b =- 0.34; P = 0.03) and adiponectin (b = 0.38;
P = 0.004) were independent of each other and also inde-
pendent of age, gender and waist circumference (Table 4).
Similar results were obtained when sTNFR2 was entered
instead of sTNFR1 into the regression model (adiponectin,
b = 0.30, P = 0.02; sTNFR2, b =- 0.48; P = 0.004)
(Table 4). Correlations between lipid oxidation during the
clamp and sTNFR1 (b = 0.41; P = 0.008) (Table 4)a n d
sTNFR2 (b = 0.41; P = 0.01) (Table 5) were independent
of adiponectin, age and waist circumference.
Discussion
In the present study, we investigated serum adiponectin,
sTNFR1 and sTNFR2 concentrations in relation to lipid
and glucose metabolism. We showed decreased serum
adiponectin concentration in obese patients and positive
correlation between this cytokine and insulin sensitivity.
There is growing evidence that adiponectin function is
closely related to the pathogenesis of insulin resistance [11,
16–18, 21, 39, 40]. In our study, serum adiponectin con-
centration was negatively correlated with the rate of lipid
oxidation during hyperinsulinemia and positively with
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Fig. 1 Relationship between serum adiponectin and glucose oxidation (a) and lipid oxidation (b) during hyperinsulinemia and relationship
between serum sTNFR1 and glucose oxidation (c) and lipid oxidation (d) during the clamp in the entire study group (n = 53)
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These results suggest that high serum adiponectin con-
centration protects from developing insulin resistance by
stimulating glucose oxidation and inhibiting lipid oxidation
during hyperinsulinemia and increasing NOGM. These
data are in agreement with Salmenniemi et al. who reported
similar results in offspring of type 2 diabetic patients [24].
Another group reported no signiﬁcant correlation between
serum adiponectin level and substrates oxidation, either
before or during the clamp [8]. However, these data were
obtained mostly from type 2 diabetic subjects, older than in
the present study. Højlund et al. showed that reduced serum
adiponectin concentration may contribute to an impaired
insulin activation of glycogen synthase in the skeletal
muscle of patients with type 2 diabetes [21]. It was also
reported that adiponectin increases GLUT4 translocation
and glucose uptake but reduces glycogen synthesis in rat
skeletal muscle [25] presumably via activation of AMP
kinase [23, 25].
Another factors that could modulate insulin sensitivity
and substrates metabolism are soluble TNF-a receptors. In
the present report, we showed an increase in serum
sTNFR1 and sTNFR2 concentration in obese patients in
comparison with the lean subjects. We also observed
negative correlation between insulin sensitivity and serum
sTNFR1 and sTNFR2 concentrations. These ﬁndings are
consistent with our previous reports [11, 13, 38]. Our data
indicate that a soluble TNF-a receptors are associated with
insulin resistance through its relationship with substrate
oxidation in hyperinsulinemic condition and NOGM.
Hotamisligil et al. reported that TNF-a is an important
mediator of insulin resistance in obesity through its ability
to decrease the tyrosine kinase activity of the insulin
receptor [41]. TNF-a has been shown to inhibit insulin-
stimulated GLUT4 translocation and glucose uptake
through inhibition of insulin signaling [9]. In experimental
study, Bruce et al. showed that TNF-a had no effect on
lipid oxidation but increased fatty acid incorporation into
DAG, which may be involved in the development of
TNF-a-induced insulin resistance in skeletal muscle [42].
Although there are studies reporting the impact of
TNF-a system on substrate oxidation, to the best of our
knowledge, this is the ﬁrst data to report such associations
in human studies in vivo. Additionally, as mentioned in the
Introduction, the human data regarding the association
between adiponectin and substrate oxidation are contro-
versial and our study provides the ﬁrst results in this ﬁeld
obtained in young and apparently healthy population, free
of potential multiple confounding factors.
The possible limitations of our study include relatively
small number of male subjects, which can affect the results
of gender and also limited number of subjects in overweight
and obese groups. However, we were able to detect signif-
icant differences in insulin sensitivity and inﬂammatory
markers between the groups when the overweight/obese
subjects were pooled together and also between lean and
obese subjects in one-way ANOVA with post hoc Tukey’s
test. Additionally, in the regression models, we observed
that some of the relationships between inﬂammatory mark-
ers and substrate oxidation were independent of age and the
measure of visceral adiposity (waist circumference).
Our data showed that soluble TNF-a receptors and
adiponectin correlated in inverse manner with insulin
Table 3 Multiple regression analysis of insulin sensitivity (M) and
age, gender, WC and adiponectin
Variable M
BP value
Age -0.096 0.411
Gender 0.203 0.082
WC -0.343 0.009
Adiponectin 0.312 0.016
WC Waist circumference, M Whole-body glucose uptake normalized
per kg of fat-free mass
Table 4 Multiple regression analysis of lipid and glucose oxidation
during the metabolic clamp and age, gender, WC, adiponectin and
sTNFR1
Variable LOx-clamp COx-clamp
BP value BP value
Age 0.0009 0.993 -0.058 0.635
Gender 0.264 0.037 -0.206 0.111
WC 0.154 0.324 -0.044 0.781
Adiponectin -0.246 0.055 0.388 0.004
sTNFR1 0.416 0.008 -0.346 0.031
WC Waist circumference, sTNFR1 Soluble TNFa receptor 1, COx-
clamp Rate of glucose oxidation during hyperinsulinemia, LOx-clamp
Rate of lipid oxidation during hyperinsulinemia
Table 5 Multiple regression analysis of lipid and glucose oxidation
during the metabolic clamp and age, gender, WC, adiponectin and
sTNFR2
Variable LOx-clamp COx-clamp
BP value BP value
Age -0.058 0.629 0.004 0.968
Gender 0.315 0.027 -0.307 0.028
WC 0.239 0.119 -0.067 0.652
Adiponectin -0.178 0.185 0.297 0.027
sTNFR2 0.406 0.018 -0.484 0.004
WC Waist circumference, sTNFR2 Soluble TNFa receptor 2, COx-
clamp Rate of glucose oxidation during hyperinsulinemia, LOx-clamp
Rate of lipid oxidation during hyperinsulinemia
22 Acta Diabetol (2012) 49:17–24
123sensitivity and they have multiple effect on substrates
metabolism during hyperinsulinemia, NOGM and meta-
bolic ﬂexibility.
The obtained results suggest that soluble TNF-a recep-
tors and adiponectin have multiple effects on glucose and
lipid metabolism in obesity.
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